Promoters of Aarti Pharmalabs Ltd. sold a 1.09% stake in the company for Rs 61.52 crore through an open market transaction on Thursday.
The Orchid Family Trust offloaded 4.97 lakh shares, or 0.54%, while the Tulip Family Trust sold 5.02 lakh shares, or 0.55%, at Rs 575 apiece, according to National Stock Exchange bulk data.
As of September 2024, Orchid Family Trust and Tulip Family Trust held 1.64% stakes each in the company.
Abakkus Asset Manager mopped up 10.69 lakh shares, or 1.17%, in the drug manufacturing firm at Rs 575.08 apiece.
Aarti Pharmalabs Q2 Performance
Aarti Pharmalabs reported a 4.1% rise in its net profit at Rs 458.03 crore for the second quarter of the fiscal 2025 as compared to Rs 439.80 crore for the same period last year.
The company's profit fell to Rs 54.62 crore, representing a 1% fall for the July-September quarter of the current fiscal as against Rs 55.45 crore for the one-year-ago period.
The pharma company's earnings before interest, tax, depreciation, and amortisation soared to Rs 93.67 crore for the three months ended Sept. 30, 2024, as compared to Rs 87.99 crore for the same quarter last year. Its margin expanded at 20.5% in the second quarter as against 20% in the same period of the previous financial year.
Aarti Pharmalabs Q2FY25 Results Highlights (YOY)
Revenue up 4.1% at Rs 458.03 crore versus Rs 439.80 crore
Net profit down 1% at Rs 54.62 crore versus Rs 55.45 crore
Ebitda up 6% at Rs 93.67 crore versus Rs 87.99 crore
Margin at 20.5% versus 20.0%
Shares of Aarti Pharmalabs closed 8.08% higher at 632.35 per share on the National Stock Exchange. In contrast, the benchmark Nifty rose 0.1%. The stock has risen 25.09% in the last 12 months and 25.35% on a year-to-date basis.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
